Tony Arulanandam

Tony Arulanandam

Company: PTC Therapeutics

Job title: Vice President & Head of Gene Therapy Nonclinical Research


Tony heads up Gene Therapy Translational Research at PTC Therapeutics and is working on multiple BLA and IND enabling gene therapy programs in the CNS and inherited retinal disease disorders areas. Tony trained as an immunologist and did his fellowship in T cell immunology at the Dana-Farber Cancer institute and Harvard Medical School and has worked several immunotherapy programs focussed on preclinical efficacy, immunogenicity and iimunotoxicity issues. He has extensive experience with the challenges with AAV delivery and immunogenicity related safety, efficacy challenges and preclinical and clinical risk mitigation strategies to support AAV gene therapy programs.


Live Q&A – Ask the speakers your questions 10:30 am

Read more

day: Day One

Understanding & Characterization of Immune Responses to AAV Gene Therapy & Preclinical & Clinical Risk Mitigation Strategies 9:00 am

• Understanding innate and adaptive immune responses to AAV gene therapy • Characterization of the immune response and strategies to monitor immune responses to AAV gene therapy • Preclinical and clinical risk mitigation strategies of AAV gene therapyRead more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.